Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia
Harryanto Reksodiputro A1,2*, Hilman Tadjoedin2, Iman Supandiman3, Nuzirwan Acang4, Azmi S. Kar5, Made Bakta I6, Andi Fachruddin Benyamin7, Ami Ashariati8, Suharti C9, Ikhwan Rinaldi1, Nadia Salim1, Wulyo Rajabto1, Nugroho Prayogo2, Demak L. Tobing2, Meilani Syampurnawati1, Johan Kurnianda10, Suradi Maryono11, Budi Darmawan Machsoes12, Mediarty Syahrir13, Darwin Prenggono M14, Harlinda Haroen Kumaat15, Resti Mulya Sari2, Sri Agustini2, Toman L. Toruan1 and Delta Fermikuri Akbar1
- Corresponding Author:
- Ary Harryanto Reksodiputro
Division of Hematology and Medical Oncology
Department of Internal Medicine
Faculty of Medicine University of Indonesia/Cipto Mangunkusumo
Jl. Diponegoro no. 71, Jakarta 10430, Indonesia
E-mail: [email protected]
Received Date: October 16, 2014; Accepted Date: April 29, 2015; Published Date: May 02, 2015
Citation: Reksodiputro AH, Tadjoedin H, Supandiman I, Acang N, Kar AS, et al. (2015) Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. J Blood Disord Transfus 6:271. doi: 10.4172/2155-9864.1000271
Copyright: © 2015 Reksodiputro AH et al.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: To assess CML patient’s characteristic including demographic, clinical and hematological characteristic of patients with CML including quantitative BCR-ABL and BCR-ABL gene sequencing.
Methods: This study was an open-label, single arm, non-randomized, cross sectional study in patients with CML being treated with imatinib mesylate (IM) from 12 centers.
Result: A total of 100 patients were evaluated between January 1, 2009 and December 31, 2011. The median age was 34-35 years old (mean of age is 36 years old), and more patients in the productive age was found. ------- (?) were 80 of the 100 patients who had been examined for the BCR-ABL gene mutation with the sequencing method before consuming IM. Mutation in the P-loop was seen in 2,27% (1 out of 44 patients), this finding was beyond our expectation since 47,69% (31 out of 65 patients) of our patients did not achieved CHR at three months. On the other hand, 15,9% (7 out of 44 patients) of our patients had mutation outside the P-loop.
Conclusions: The characteristics of CML patients in Indonesia were not different from CML patients in Asia in general. Our finding concerning the high frequency mutation in the BCR-ABL gene outside the P-loop needs further study.